GammaDelta spins out Adaptate to focus on antibody therapies

As GammaDelta nears bringing its T cell therapies to the clinic, it’s spinning out Adaptate to focus on the development of its γδ antibody-based programs.

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;

Read the full 295 word article

How to gain access

Continue reading with a
two-week free trial.